AbCellera Biologics
ABCL
ABCL
138 hedge funds and large institutions have $272M invested in AbCellera Biologics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less call options, than puts
Call options by funds: $407K | Put options by funds: $837K
Holders
138
Holding in Top 10
1
Calls
$407K
Puts
$837K
Top Buyers
| 1 | +$17.5M | |
| 2 | +$4.78M | |
| 3 | +$3.17M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.56M |
| 5 |
Two Sigma Investments
New York
|
+$1.23M |
Top Sellers
| 1 | -$23.4M | |
| 2 | -$15.7M | |
| 3 | -$11.2M | |
| 4 |
EAM
Exome Asset Management
New York
|
-$1.52M |
| 5 |
FFGM
Founders Fund Growth Management
San Francisco,
California
|
-$1.2M |